Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04239703 · ClinicalTrials.gov registry record
Trifecta-Kidney cfDNA-MMDx Study
A clinical trial of Kidney Transplant Rejection, sponsored by University of Alberta.
- Recruiting
- Registry status
- 300
- Enrollment target
- 20
- Study locations
NCT04239703: Recruiting study of Kidney Transplant Rejection, sponsored by University of Alberta.
NCT04239703 is a study of Kidney Transplant Rejection that is actively recruiting participants, run by University of Alberta. The registered enrollment target is 300 participants, below the 768-participant average among 8 other Kidney Transplant Rejection trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04239703, a study of Kidney Transplant Rejection, is actively recruiting participants, sponsored by University of Alberta.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.
Primary Outcome
Calibration of DD-cfDNA test cut-off values against the probability of T cell-mediated rejection in the biopsy as reported by MMDx.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Prospera
- DIAGNOSTIC_TEST HLA antibody
- DIAGNOSTIC_TEST MMDx
Study Locations (20)
Other
- Department of Nephrology, The Royal Melbourne Hospital 1 South East - Melbourne
- University Hospital Merkur Renal Division - Zagreb
- Institute for Clinical and Experimental Medicine (IKEM) - Prague
- Charite-Medical University of Berlin Department of Nephrology - Berlin
- Centre of Nephrology, Vilnius University Hospital Santaros Klinikos - Vilnius
- Department of Nephrology and Transplantation Medical University in Bialystok - Bialystok
- University Hospital nr1 Bydgoszcz, Klinika Transplantologii - Bydgoszcz
Maryland
- University of Maryland School of Medicine - Baltimore
- The Johns Hopkins University, School of Medicine - Baltimore
Michigan
- Detroit Medical Center, Harper University Hospital of Wayne State University - Detroit
- Henry Ford Hospital - Detroit
Ohio
- University Hospitals Cleveland Medical Ctr. - Cleveland
- Cleveland Clinic - Cleveland
Florida
- Tampa General Hospital - Tampa
Missouri
- Barnes-Jewish Hospital, Washington University at St. Louis - St Louis
Utah
- Intermountain Transplant Services - Murray
Virginia
- Virginia Commonwealth University Medical Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2019-12-01 |
| Est. Completion | 2027-12 |
What NCT04239703 shows while recruiting
NCT04239703 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 768-participant average among 8 other Kidney Transplant Rejection trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Kidney Transplant Rejection appearing as the primary indexed condition, and to 3 interventions - of which Prospera is the first listed.
NCT04239703 names 20 study sites across 11 states, led by Other, Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT04239703 about?
NCT04239703 is a clinical study titled "Trifecta-Kidney cfDNA-MMDx Study". Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.
What is the current status of trial NCT04239703?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2019-12-01. Estimated completion is 2027-12.
What conditions does trial NCT04239703 study?
This clinical trial studies the following conditions: Kidney Transplant Rejection.
What interventions are being tested in trial NCT04239703?
The interventions under investigation include: Prospera (DIAGNOSTIC_TEST), HLA antibody (DIAGNOSTIC_TEST), MMDx (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04239703?
This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04239703 being conducted?
This trial has 20 study locations across Florida, Maryland, Michigan, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04239703's enrollment target sits among peer trials
300 3rd of 8 higher than 6 of 8 other Kidney Transplant Rejection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplant Rejection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
RECRUITING
-
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA
RECRUITING
-
Microbiome and Immunosuppression: The Mission Study
ACTIVE NOT RECRUITING
-
The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
ACTIVE NOT RECRUITING
-
Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection
ACTIVE NOT RECRUITING
-
Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI